Image Sourced Mach7 Technologies Limited
Market Herald logo


Be the first with the news that moves the market

Mach7 Technologies has announced an increase of 19 per cent, for its third quarterly report, with a total of $3.1 million in new sale orders for the innovative data management company.

Mach7 proudly won Sampson Regional Medical Centre and Loyola University Health System which has enabled its number of sales orders to increase significantly. 

As a result of Mach7’s strong sales growth, its annual recurring revenue under contract (“CARR”) has reached $7.6 million since the end of the last quarter. This is a 13 per cent growth increase in revenue.  Mach7 has also announced positive progress on its Hospital Authority Hong Kong (“HAHK”) Project.

The Company received purchase orders of $1.7 million from the Project and will be recognised as revenue in full in FY 2019. Further purchase orders are still expected. 

Following the Company’s recent success, it is well on track to deliver its 12-month free cash flow breakeven target for the period ending February 2020.

Please find the announcement attached

M7T by the numbers
More From The Market Herald
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) to raise $6m for cell therapies

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors for a $4.57 million…

" Radiopharm Theranostics (ASX:RAD) acquires IP ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics (ASX:RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
Nuheara (ASX:NUH) - CEO, Justin Miller

" Nuheara (ASX:NUH) completes $1.06m SPP

Hearing technology company Nuheara (ASX:NUH) has completed its share purchase plan (SPP) with applications totalling $1,067,200.
Anteris Technologies (ASX:AVR) - Chief Executive, Wayne Paterson

" Anteris Technologies (ASX:AVR) reports positive data from first-in-human heart valve trial

Meditech specialist Anteris Technologies (ASX:ARV) has reported "excellent" results from the first-in-human trial of its DurAVR…